Literature DB >> 20029442

Hematology: ATG and Newton's third law of motion.

Claudio G Brunstein1.   

Abstract

Patients with hematological malignancies have a risk of developing graft-versus-host disease (GVHD) following allogeneic hematopoietic stem-cell transplantation. The addition of ATG to prophylaxis regimens decreases the incidence of GVHD without compromising overall survival in these patients.

Entities:  

Year:  2010        PMID： 20029442     DOI： 10.1038/nrclinonc.2009.192

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  8 in total

Review 1.  Peripheral blood stem cells for allogeneic transplantation: a review.

Authors:  C Cutler; J H Antin
Journal:  Stem Cells       Date:  2001       Impact factor: 6.277

2.  Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

Authors:  Joost W J van Esser; Hubert G M Niesters; Bronno van der Holt; Ellen Meijer; Albert D M E Osterhaus; Jan Willem Gratama; Leo F Verdonck; Bob Löwenberg; Jan J Cornelissen
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

3.  Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).

Authors:  A Bacigalupo; T Lamparelli; P Bruzzi; S Guidi; P E Alessandrino; P di Bartolomeo; R Oneto; B Bruno; M Barbanti; N Sacchi; M T Van Lint; A Bosi
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

4.  Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.

Authors:  John E Wagner; John S Thompson; Shelly L Carter; Nancy A Kernan
Journal:  Lancet       Date:  2005 Aug 27-Sep 2       Impact factor: 79.321

5.  A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies.

Authors:  Jan J Cornelissen; Bronno van der Holt; Eefke J Petersen; Lars Vindelov; Charlotte A Russel; Martin Höglund; Johan Maertens; Harry C Schouten; Eric Braakman; Monique M C Steijaert; Mark J M Zijlmans; Ineke Slaper-Cortenbach; Marc A Boogaerts; Bob Löwenberg; Leo F Verdonck
Journal:  Exp Hematol       Date:  2003-10       Impact factor: 3.084

6.  Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

Authors:  Jürgen Finke; Wolfgang A Bethge; Claudia Schmoor; Hellmut D Ottinger; Matthias Stelljes; Axel R Zander; Liisa Volin; Tapani Ruutu; Dominik A Heim; Rainer Schwerdtfeger; Karin Kolbe; Jiri Mayer; Johan A Maertens; Werner Linkesch; Ernst Holler; Vladimir Koza; Martin Bornhäuser; Hermann Einsele; Hans-Jochem Kolb; Hartmut Bertz; Matthias Egger; Olga Grishina; Gérard Socié
Journal:  Lancet Oncol       Date:  2009-08-18       Impact factor: 41.316

Review 7.  Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond.

Authors:  M Mohty
Journal:  Leukemia       Date:  2007-04-05       Impact factor: 11.528

Review 8.  B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome.

Authors:  T G Gross; M Steinbuch; T DeFor; R S Shapiro; P McGlave; N K Ramsay; J E Wagner; A H Filipovich
Journal:  Bone Marrow Transplant       Date:  1999-02       Impact factor: 5.483
  8 in total
  1 in total

Review 1.  Novel cord blood transplant therapies.

Authors:  Elizabeth J Shpall; Catherine M Bollard; Claudio Brunstein
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-15       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.